文献速递肝病

2型糖尿病与肥胖人群中MASLD的诊断与非无创评估

Diagnosis and non-invasive assessment of MASLD in type 2 diabetes and obesity.
PubMed 文献 · Aliment Pharmacol Ther · 2024-01-01

本文为叙述性综述,检索PubMed和Cochrane数据库1990年至2023年8月的文献,评估无创检测诊断MASLD的性能与局限,重点关注糖尿病和肥胖的影响。腹部超声仍是诊断肝脂肪变的主要方法,磁共振质子密度脂肪分数是量化脂肪变的金标准;简单纤维化评分如FIB-4适用于基层排除进展期纤维化,但阳性预测值低,异常者需进一步血液或影像学检查;部分纤维化无创检测在糖尿病患者中准确性较低,肥胖影响超声和瞬态弹性成像性能。

要点

  • 腹部超声是诊断肝脂肪变的主要方法,磁共振质子密度脂肪分数是量化脂肪变的金标准。
  • FIB-4等简单纤维化评分适用于基层初筛排除进展期纤维化,但阳性预测值低,异常者需进一步检查。
  • 部分纤维化无创检测在糖尿病患者中准确性较低,肥胖影响超声和瞬态弹性成像性能。

核心结论

  • 本文强调2型糖尿病和肥胖患者中MASLD无创检测临床应用的相关问题。

研究设计与样本

  • 叙述性综述,检索PubMed和Cochrane数据库1990年至2023年8月发表的文献。

主要发现

  • 腹部超声仍是诊断肝脂肪变的主要方法,磁共振质子密度脂肪分数是量化脂肪变的金标准。
  • FIB-4等简单纤维化评分适用于基层和非肝病科室初筛排除进展期纤维化和未来肝脏相关并发症风险。
  • FIB-4阳性预测值低,异常时应进一步行特异性血液生物标志物(如增强肝纤维化评分)或影像学纤维化标志物(如振动控制瞬态弹性成像和磁共振弹性成像)检查。
  • 部分纤维化无创检测在糖尿病患者中准确性较低。
  • 肥胖影响腹部超声和瞬态弹性成像的性能,而磁共振成像在部分重度肥胖患者中可能不可行。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) is currently the most common chronic liver disease and an important cause of cirrhosis and hepatocellular carcinoma. It is strongly associated with type 2 diabetes and obesity. Because of the huge number of patients at risk of MASLD, it is imperative to use non-invasive tests appropriately. AIMS: To provide a narrative review on the performance and limitations of non-invasive tests, with a special emphasis on the impact of diabetes and obesity. METHODS: We searched PubMed and Cochrane databases for articles published from 1990 to August 2023. RESULTS: Abdominal ultrasonography remains the primary method to diagnose hepatic steatosis, while magnetic resonance imaging proton density fat fraction is currently the gold standard to quantify steatosis. Simple fibrosis scores such as the Fibrosis-4 index are well suited as initial assessment in primary care and non-hepatology settings to rule out advanced fibrosis and future risk of liver-related complications. However, because of its low positive predictive value, an abnormal test should be followed by specific blood (e.g. Enhanced Liver Fibrosis score) or imaging biomarkers (e.g. vibration-controlled transient elastography and magnetic resonance elastography) of fibrosis. Some non-invasive tests of fibrosis appear to be less accurate in patients with diabetes. Obesity also affects the performance of abdominal ultrasonography and transient elastography, whereas magnetic resonance imaging may not be feasible in some patients with severe obesity. CONCLUSIONS: This article highlights issues surrounding the clinical application of non-invasive tests for MASLD in patients with type 2 diabetes and obesity.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Chan WK, Petta S, Noureddin M, et al. Diagnosis and non-invasive assessment of MASLD in type 2 diabetes and obesity. Aliment Pharmacol Ther. 2024. PMID: 38813831. doi:10.1111/apt.17866

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。